Академический Документы
Профессиональный Документы
Культура Документы
Simvastatin Survival
Study (4S)
Simvastatin 20 mg/day or
matching placebo
Study Goal:
TC 116-200 mg/dL
The Lancet, Vol 344, November 19, 1994
Dosage Titration
4,444
randomized patients
2,221 2,223
simvastatin 20 mg/day placebo patients
20 mg/day 40 mg/day
63% 37%
100
98
96
94
92
% Surviving
90
88 30%
86 Simvastatin risk reduction
84 p = 0.0003
Placebo
82
80
0 1 2 3 4 5 6
Years since randomization
150 p<0.00001
100 111
50
0
Placebo Simvastatin
-Probable acute MI 5 5
-Sudden death 78 46
-Other 43 30
Cerebrovascular 12 14
Other cardiovascular 6 11
Noncoronary 18 25
vascular
Non-cardiovascular 49 46
-Cancer 35 33
-Suicide 4 5
-Trauma 3 1
-Other 7 7
11.5%
8.2%
189
111
18 25
35 33
14 13
Placebo Simvastatin
100
% of patients without events
90
80 34%
Risk Reduction
70
p<0.00001 Simvastatin
Placebo
60
0 1 2 3 4 5 6
Years since randomization
100
Simvastatin
% of patients without
95
Placebo
PTCA/CABG
90
85 37%
80
Risk
Reduction
75 p<0.00001
70
0 1 2 3 4 5 6
Years since randomization
35
29.4
30 Placebo
25 Simvastatin
% Incidence
20.5 21.7
20
14.5
15 12.8
10 8.5
6 6.6
5
0
Male Female Male Female
Total Mortality Major Coronary Events
35
30 Placebo 27.6 28.3
Simvastatin
25
% Incidence
21
20 17.6
14.8
15
11
10 8.1
5.2
5
0
<60 yrs >60 yrs <60 yrs >60 yrs
Total Mortality Major Coronary Events
110
Simvastatin
% of patients alive without
100
an atherosclerotic event
Placebo
90
80 26%
Risk
70
Reduction
60 p<0.00001
50
0 1 2 3 4 5 6
Years since randomization
The Lancet, Vol 344, November 19, 1994
Changes in Lipoprotein Levels
Simvastatin vs placebo, at study end
20
8 7 7
10
1 1
0
% Change
-10
-10
-20
-30 -25 Simvastatin
-40 -35 Placebo
-50
TC LDL HDL TGs
The Lancet, Vol 344, November 19, 1994
Safety Profile
Placebo Simvastatin
# of patients with (n=2223) (n=2221)
Nonfatal cancer 61 57
AST 3x ULN 23 20
ALT 3x ULN 33 49
Rhabdomyolisis 0 1
Major coronary
events p<0.00001
PTCA/CABG p<0.00001
Event-free p<0.00001
survival
0.2 0.4 0.6 0.8 1.0 1.2
Relative risk (95% CI)
Reduced
Reduced Increased
Increased
The Lancet, Vol 344, November 19, 1994
Endpoint Relative Comment
Risk
• Overall Risk of Death 30% Only trial to date with cholesterol lowering agent to definitively
showreduction in total or coronary mortality
• Risk of Coronary Death 42% Cardiovascular disease is the world’s leading cause of death
accounting for one-fourth of all deaths
• Risk of Major Coronary Includes death from coronary disease and non-fatal heart attacks
Events 34%
• Risk of Revascularization Includes percutaneous coronary angioplasties (PTCA) and coronary
artery bypass grafts (CABG).
Procedures 37%
• Event - free Survival 26% Finished the study without suffering any coronary events or other
atheroscleotic events such as stroke
• LDL Cholesterol Human atherosclerotic plaques primarily contain LDL cholesterol
38%*
• HDL Cholesterol High concentrations of HDL may protect against coronary heart
disease.
8%*
* After
• Total 6 weeks of treatment with 20mg
Cholesterol Simvastatin is the most effective cholesterol-lowering agent available
at recommended doses
28%*
4S Summary
Compared with Placebo, Simvastatin:
• Improved survival
• Reduced coronary mortality
• Reduced major coronary events
• Reduced need for PTCA and CABG
Improved event-free survival
• Substantially reduced TC and LDL